Detalhe da pesquisa
1.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
N Engl J Med
; 389(2): 148-157, 2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272527
2.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Blood
; 143(6): 496-506, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879047
3.
Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
Blood
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635762
4.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34891224
5.
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Blood
; 142(7): 621-628, 2023 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37319432
6.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood
; 141(19): 2307-2315, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821768
7.
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Blood
; 139(5): 686-689, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788401
8.
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Blood
; 140(8): 851-860, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679476
9.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
Ann Hematol
; 103(1): 185-198, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851072
10.
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Am J Hematol
; 99(5): 880-889, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504387
11.
Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States.
Value Health
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38641058
12.
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
Ann Intern Med
; 176(12): 1625-1637, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048587
13.
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.
Br J Haematol
; 202(2): 248-255, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129856
14.
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
Br J Haematol
; 203(5): 774-780, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584155
15.
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
N Engl J Med
; 382(14): 1331-1342, 2020 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242358
16.
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
Blood
; 137(10): 1353-1364, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871584
17.
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy.
Haematologica
; 108(11): 2972-2981, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317884
18.
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
JAMA
; 330(6): 528-536, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552303
19.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 23(1): 91-103, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34895487
20.
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Lancet Oncol
; 22(10): 1391-1402, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534514